Clinical trial
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin +…
NCT02657434 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02657434 |
|---|---|
| Title | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) |
| Official title | A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Atezolizumab, Carboplatin, Cisplatin, Pemetrexed |
| Enrollment | 578 |
| Start date | Apr 30, 2016 |
| Primary completion | Jul 18, 2019 |
| Completion | Dec 13, 2022 |
| First posted | Jan 15, 2016 |
| Last update posted | Nov 21, 2023 |
| Countries | Argentina, Australia, Austria, Belgium, Bulgaria, Chile, China, France, Hungary, Ireland, Israel, Italy and 15 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: